FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * YANG MICHAEL J. 2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ ACAD ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP and CCO
(Last)         (First)         (Middle)
C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, STE. 300
3. Date of Earliest Transaction (MM/DD/YYYY)
7/7/2020
(Street)
SAN DIEGO, CA 92130
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  7/7/2020    M    7500  A $19.98  12704  D   
Common Stock  7/7/2020    M    5000  A $21.28  17704  D   
Common Stock  7/7/2020    M    14750  A $25.12  32454  D   
Common Stock  7/7/2020    S(1)    16150  D $56.0503 (2) 16304  D   
Common Stock  7/7/2020    S(1)    11100  D $56.5382 (3) 5204  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $19.98  7/7/2020    M        7500    (4) 4/17/2028  Common Stock  7500  $0.00  570000  D   
Stock Option (Right to Buy)  $21.28  7/7/2020    M        5000    (5) 10/14/2028  Common Stock  5000  $0.00  25000  D   
Stock Option (Right to Buy)  $25.12  7/7/2020    M        14750    (6) 4/29/2029  Common Stock  14750  $0.00  44292  D   

Explanation of Responses:
(1)  The sales reported in this Form 4 were effected pursuant to an amended Rule 10b5-1 stock sale plan dated May 12, 2020.
(2)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 to $56.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
(3)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.395 to $56.685, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
(4)  25% of the 600,000 shares originally subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments
(5)  25% of the 40,000 shares originally subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments.
(6)  25% of the 59,042 shares originally subject to the Stock Option vested and became exercisable on April 29, 2020. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
YANG MICHAEL J.
C/O ACADIA PHARMACEUTICALS INC.
3611 VALLEY CENTRE DRIVE, STE. 300
SAN DIEGO, CA 92130


EVP and CCO

Signatures
/s/ Austin D. Kim, Attorney-in-Fact 7/9/2020
**Signature of Reporting Person Date